Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trinity Biotech ( (TRIB) ) has issued an announcement.
On December 22, 2025, Trinity Biotech entered into a second amendment to its Sixth Amended and Restated Credit Agreement with Perceptive Credit Holdings III, L.P., adding a further $5 million term loan, extending the facility’s maturity to January 15, 2027, and replacing a planned non-convertible note with a convertible promissory note that allows up to $60 million of principal to be converted into ADSs at a discount to market price, subject to a floor of $1.03 and a 9.9% ownership cap. On the same date, Trinity Biotech and its subsidiary TRIB Biosensors Inc. also reached a conversion rights agreement with Perceptive Credit Holdings II, L.P. that allows a $5 million milestone payment and a renegotiated $7.5 million contingent payment tied to the Waveform acquisition to be settled, in whole or in part, in ADSs at VWAP-based prices, effectively equitizing a significant portion of the group’s debt obligations and contingent liabilities; if all conversion rights under these arrangements are exercised at the floor price, the company could issue up to about 69.9 million ADSs, materially diluting existing shareholders but improving liquidity and pushing out debt maturities.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.
Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. Technical analysis shows mixed signals, with short-term bullish momentum but potential for a pullback. Valuation metrics are unattractive due to negative earnings and lack of dividends.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is an Ireland-based diagnostics company that develops, manufactures and markets medical diagnostic products, including point-of-care and laboratory-based tests, to healthcare providers and laboratories worldwide. The company’s capital structure includes American Depositary Shares (ADSs) representing its A ordinary shares, which it uses as a financing tool in its credit arrangements with institutional lenders.
Average Trading Volume: 101,970
Technical Sentiment Signal: Sell
Current Market Cap: $16.25M
For a thorough assessment of TRIB stock, go to TipRanks’ Stock Analysis page.